Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 7/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.46 |
| ▸ | PPARA | Q07869 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGAV | P06756 | 1/20 | 0.44 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31407804 | 1.00 | ACE (0.55) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL14860326 | 1.00 | ACE (0.55) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL19304674 | 1.00 | ACE (0.55) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL14861192 | 0.91 | KLK5 (0.51) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL16228244 | 0.91 | KLK5 (0.51) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL31407628 | 0.86 | ACE (0.57) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL31407738 | 0.82 | ITGA4 (0.56) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL6162390 | 0.82 | PTPN1 (0.54) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL6162397 | 0.82 | PTPN1 (0.54) | ACEITGB3ITGA2BPTPN1ITGA4 | |
| SCHEMBL25355776 | 0.81 | LOX (0.49) | PTPN1ITGA4ITGB7PPARGITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | ACE 1944/4885ITGB3 2864/4885ITGA2B 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.